News Oral Wegovy bolsters Novo in Q3 Novo has raised its financial guidance for 2026 on the back of rising sales of its oral weight-loss therapy Wegovy.
News CagriSema helps women lose 25% of their weight in study Novo continues to build the case for its new weight-loss candidate CagriSema, pointing to new data that show strong efficacy in women.
News Under pressure, Novo lays out blockbuster launch plans Novo has revealed a plan to launch five or more blockbusters between now and 2030 that it hopes will grow annual revenues by around $23bn.
News Novo fails to shrug off investor concern at Q2 update Novo Nordisk's better-than-expected second-quarter revenues can't outweigh worries about oral Wegovy growth and another CagriSema disappointment.
News US judge says Novo Nordisk must face lawsuit over CagriSema A US judge has ruled that Novo Nordisk must face a lawsuit claiming it defrauded investors with misleading statements about a pivotal CagriSema study.
News ADA: Lilly's weight-loss reveal, and wannabes display wares Lilly reveals more details of its retatrutide obesity and diabetes studies, plus trial updates from Zealand/Roche, Pfizer, Novo Nordisk, and Sciwind.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.